Recurrence Is Low One Year After Eradication of H. pylori Infection

Share this content:
Recurrence Is Low One Year After Eradication of <i>H. pylori</i> Infection
Recurrence Is Low One Year After Eradication of H. pylori Infection

FRIDAY, Dec. 30, 2016 (HealthDay News) -- The recurrence of Helicobacter pylori infection one year after eradication is low, according to a study published online Dec. 27 in the Journal of Digestive Diseases.

Li Ya Zhou, from the Peking University Third Hospital in Beijing, and colleagues assessed the recurrence rate of H. pylori infection among 827 patients receiving successful H. pylori eradication in a previous randomized controlled trial. A 13C-urea breath test was administered one year after eradication therapy.

The researchers found that based on an 89.8 percent follow-up rate (743 patients), the annual recurrence rate of H. pylori infection was 1.75 percent (13 patients). Questionnaires completed by 692 patients (13 recurrence and 679 non-recurrence) showed that peptic ulcer disease (odds ratio [OR], 3.385), contact with other individuals with H. pylori infection (OR, 4.231), and hospitalization (OR, 9.302) were independent risk factors for H. pylori infection recurrence.

"The recurrence of H. pylori infection one year after eradication is low in urban population of China," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Post-Deployment Screening Has Limited Benefit in U.K. Military

Post-Deployment Screening Has Limited Benefit in U.K. Military

Screening based on tailored advice does not reduce prevalence of disorders or increase help-seeking

Excess BMI Ups Risk of T1DM in Autoantibody-Positive Relatives

Excess BMI Ups Risk of T1DM in Autoantibody-Positive ...

Increased diabetes progression risk occurred at lower cumulative excess BMI index in children <12

Baricitinib Associated With Significant Improvement in RA

Baricitinib Associated With Significant Improvement in RA

Findings versus placebo, adalimumab in patients non-responsive to methotrexate

is free, fast, and customized just for you!

Already a member?

Sign In Now »